# Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)

> **NCT00948389** · PHASE1,PHASE2 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 28 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Dasatinib
- **DRUG:** Lomustine

## Key facts

- **NCT ID:** NCT00948389
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-10
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** Inability to meet protocol objectives
- **Last updated:** 2012-08-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00948389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00948389, "Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00948389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*